Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ClinicalTrials.gov Noncompliance Remains An FDA Concern

Executive Summary

The pharmaceutical industry's failure to list cancer trial information on ClinicalTrials.gov remains a concern to FDA, Oncology Drug Products Division Director Richard Pazdur, MD, said May 12
Advertisement

Related Content

FDA Unlikely To Act Unilaterally To Increase ClinicalTrials.gov Postings
ClinicalTrials.gov Compliance Will Improve, PhRMA Tells Rep. Waxman
FDA Unlikely To Act Unilaterally To Increase ClinicalTrials.gov Postings
HHS Registry Of Clinical Trials Proposed By AMA To Limit Publication Bias
GSK Posts Paxil Pediatric Data On Website; Plans U.S. Clinical Trial Register
Clinicaltrials.gov: Rep. Waxman Asks PhRMA To Describe Compliance Efforts
Cancer Drug Development To See “Vast Improvements” In Speed – Thompson
ClinicalTrials.Gov Registry Needs Legislative Boost, JAMA Editorial Says
ClinicalTrials.gov Postings By Industry Increase, But Still Appear Incomplete
ClinicalTrials.gov Postings By Industry Increase, But Still Appear Incomplete
Advertisement
UsernamePublicRestriction

Register

PS043961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel